1. Home
  2. UTL vs NGNE Comparison

UTL vs NGNE Comparison

Compare UTL & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNITIL Corporation

UTL

UNITIL Corporation

N/A

Current Price

$53.99

Market Cap

906.9M

Sector

Utilities

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$38.13

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UTL
NGNE
Founded
1984
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.9M
744.9M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
UTL
NGNE
Price
$53.99
$38.13
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$56.50
$63.57
AVG Volume (30 Days)
80.3K
203.0K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
3.65%
N/A
EPS Growth
1.37
0.93
EPS
2.11
N/A
Revenue
$536,000,000.00
N/A
Revenue This Year
$5.43
N/A
Revenue Next Year
$4.22
N/A
P/E Ratio
$25.45
N/A
Revenue Growth
8.33
N/A
52 Week Low
$45.17
$15.93
52 Week High
$57.26
$43.66

Technical Indicators

Market Signals
Indicator
UTL
NGNE
Relative Strength Index (RSI) 53.96 53.11
Support Level $49.70 $35.26
Resistance Level $54.96 $42.84
Average True Range (ATR) 0.96 2.62
MACD 0.02 -0.11
Stochastic Oscillator 63.22 40.59

Price Performance

Historical Comparison
UTL
NGNE

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: